Could a bladder pill cool down breast cancer hot flashes?
NCT ID NCT01530373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs—solifenacin (used for overactive bladder) and clonidine (a common hot flash treatment)—to see which better reduces hot flashes in breast cancer patients on hormone therapy. About 110 women will take one of the pills daily for three weeks and track their symptoms. The goal is to find a more effective way to ease this common side effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
solifenacin (Vesicare) and clonidine (Catapres, Dixarit)
What this could lead to
If solifenacin works better than clonidine, it could offer a new option for managing hot flashes in breast cancer survivors.
What could go wrong
This is a small, early-phase study with only 110 participants. The drug may not prove more effective than clonidine, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 722205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact